Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7122747 | 0.94 | — | — | |
| SCHEMBL7123244 | 0.93 | — | — | |
| SCHEMBL7115081 | 0.80 | TDP1 (0.39) | MAOB | |
| SCHEMBL4973320 | 0.65 | KDM4E (0.33) | — | |
| SCHEMBL4972122 | 0.64 | GAA (0.31) | — | |
| SCHEMBL11561272 | 0.57 | MAPT (0.41) | — | |
| SCHEMBL8738128 | 0.55 | MAPT (0.54) | MAOAMAOB | |
| SCHEMBL10964201 | 0.53 | USP2 (0.40) | — | |
| SCHEMBL7124635 | 0.53 | F10 (0.55) | — | |
| SCHEMBL28351715 | 0.52 | MAPT (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | BERRYMAN KENT ALAN (US) | 2003-10-02 | — | — | US | claimed |
| US-6509335-B1 | This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of | WARNER-LAMBERT COMPANY | 2003-01-21 | — | — | US | claimed |
| EP-1068191-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-17 | — | — | EP | claimed |
| WO-1999050257-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | claimed |
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | BERRYMAN KENT ALAN (US) | 2003-10-02 | — | — | US | disclosed |
| US-6509335-B1 | This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of | WARNER-LAMBERT COMPANY | 2003-01-21 | — | — | US | disclosed |
| EP-1068191-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999050257-A1 | BENZOXAZINONES/BENZOTHIAZINONES AS SERINE PROTEASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187256-A1 | Benoxazinones/benzothiazinones as serine protease inhibitors | HABP2, SPINT2, SERPINB1 | MAOA 340/4885MAOB 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.